intake at recruitment did not show differences in total mortality, thromboembolic events and bleedings, while the astreated analysis, accounting for treatment switch, showed that patients taking OAT at recruitment had a significantly lower mortality than those not taking it [hazard ratio, 
Introduction
Data on the risk/benefit ratio of warfarin in patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) continue to be inconclusive, despite the high prevalence of arrhythmias in this population. Some authors report an increased risk of complications derived from the use of oral anticoagulant therapy (OAT) in haemodialysis (HD) patients with AF, without any benefit in terms of thromboembolic risk protection [1, 2] . Other studies are less negative [3, 4] , but a big uncertainty remains on how to approach these patients [5] . One major problem is the lack of prospective and randomized data. In fact, almost all published studies are based on retrospective analyses of registry data. Recently, a large retrospective study showed that warfarin was associated with a reduced mortality in a cohort of HD patients with newly diagnosed AF [6] . This study accounted for confounding by indication using a propensity score, but being a registry study not all potential confounders were available; in particular, the international normalized ratio (INR) was missing and OAT assumption was based on the prescription. We conducted a prospective study in a population of HD patients with AF, where information on the exact time of the eventual withdrawal of warfarin and on the INR values in subjects taking OAT were collected, over the baseline characteristics of patients. Preliminary results on 2 years of follow-up indicated that warfarin significantly increased the incidence of bleeding without reducing thromboembolic events. Furthermore, the study suggested the presence of a trend towards better survival in patients receiving OAT [7] . However, those early results needed to be completed with a long-term efficacy and safety evaluation of warfarin assumption.
The main purpose of the present study was to evaluate prospectively, in a cohort of patients with ESRD and AF followed-up for 4 years, the relationship between OAT and mortality, thromboembolic risk and haemorrhagic risk. We evaluated long-term efficacy and safety of OAT using a causal method approach to limit the confounding by indication and to account for the updated value of confounders/variables over the follow-up. The secondary aim was to test the predictive value of the CHA 2 DS 2 -VAS c (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, vascular disease, age 65-74 years, sex category) and HAS-BLED (hypertension, abnormal renal and liver function, stroke, bleeding, labile INRs, elderly age, drugs/alcohol) scores with respect to mortality, thromboembolic events and haemorrhagic events, given that these scores are indicated by the Cardiology Guidelines to identify patients at increased thromboembolic and haemorrhagic risk [8] , respectively, but were developed in cohorts of patients in which HD was an exclusion criterion.
Subjects and methods
All patients alive and under observation in ten Italian dialysis centres on 31/10/2010 were considered (n = 1529) and their clinical charts reviewed for eligibility for the study. Peritoneal dialysis patients were not included. All subjects with at least one documented paroxysmal (self-terminating) or persistent (required termination by pharmacological or electrical cardioversion) AF episode, or with permanent AF (when there has been a joint decision by the patient and clinician to cease further attempts to restore and/or maintain sinus rhythm) were recruited, giving a total of 290 patients (see Supplementary Fig. 1 ).
At recruitment, data were collected on: the presence of hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg before the beginning of the HD session or anti-hypertensive drugs administration), diabetes mellitus, peripheral artery disease (clinical presence of claudication and/or evidence of significant stenosis of main arterial trunks by Doppler examination), ischemic heart disease (previous myocardial infarction or coronary revascularization procedures and/or previous hospitalization due to acute coronary syndrome), heart failure (presence of left-ventricular dysfunction-left-ventricular ejection fraction <50%-and/or previous hospitalization due to acute or chronic heart failure), previous strokes (ischemic or haemorrhagic defined by computed tomography scan or nuclear magnetic resonance), and major bleeding episodes (haemorrhagic episodes requiring hospitalization or blood transfusion, or causing a haemoglobin plasma level reduction >2 g/dl), and on administration of antiplatelets and anticoagulants [7] .
Cardiac ultrasound examination was performed in all patients during the mid-week dialysis interval. Collected echocardiography data were: left ventricular ejection fraction (LVEF, %) and the presence of left ventricular hypertrophy (LVH), which was defined as left-ventricular mass normalized for body surface area >125 g/m 2 according to the Penn-cube formula, or when its presence was described in the report.
Patients were prospectively followed for 4 years (until 31/10/2014 or death) and their clinical charts were updated at each dialysis session. New onset of permanent AF, stroke, bleeding, cardiovascular events (ischemic and heart failure episodes that required hospitalization), and antiplatelet and anticoagulant treatment modifications were recorded.
In patients taking OAT, the INR values were assessed at least once a month and the percentage time in the target INR range (target therapeutic range, TTR) was calculated [9] . Only one centre referred patients to a Thrombosis Clinic, while in the others the nephrologist took care of warfarin dosage (the policy was to keep INR between 2 and 3). Thromboembolic and haemorrhagic risk was calculated using the CHA 2 DS 2 -VAS c and HAS-BLED scores, respectively [8] .
Procedures were performed according to the Helsinki declaration for ethical treatment of human subjects and approved by the local ethical committee. Informed consent was obtained from the enrolled subjects.
Statistical methods
All data were centrally reviewed. Patients were considered as "under OAT at recruitment" if taking OAT at 31/10/2010. Rates of mortality, thromboembolic and haemorrhagic events were computed for patients on vs. not on OAT at recruitment and compared by the Poisson model.
Marginal structural models
In order to evaluate the effect of OAT on mortality, thromboembolic risk and haemorrhagic risk, we created a pseudo-population (that mimics a randomized trial) which mitigates the selection bias in OAT treatment assignment at recruitment [10] . This pseudo-population, created by the use of (stabilized) inverse probability of treatment (and censoring) weights (IPTW), was labelled the "IPTW cohort". IPTW patients were computed by a multivariable logistic model on the propensity to be under OAT at recruitment that included age, diabetes mellitus, ischemic and bleeding/haemorrhagic strokes, ischemic heart disease, CHA 2 DS 2 -VAS c and HAS-BLED score, type of AF, LVEF <50% and LVH (and their first degree interactions), gender, dialytic age, hypertension, heart failure, peripheral artery disease and antiplatelet therapy. In order to evaluate the balance induced by these weights, the confounders among patients under OAT and not in this pseudo-population were compared by standardized differences [11] . Furthermore, an inverse probability of censoring weight was also applied to account for loss to follow-up and informative censoring due to death when analysing thromboembolic and haemorrhagic outcomes. Final weights were computed as the product of the stabilized weights [10] for treatment and censoring (trimming was not necessary as weights ranged between 0.5 and 9.5).
The weighted Cox regression model with robust standard error was applied to the IPTW cohort to assess the effect of OAT administration at recruitment on different relevant endpoints. The model was adjusted for each covariate which after balancing (IPTW cohort) still showed a standardized difference >10% between the two groups (i.e. bleeding/haemorrhagic stroke and permanent AF). Results of the Cox models are expressed in terms of estimated hazard ratios (HR), 95% confidence intervals (95% CI) and p values.
In analogy to a randomized trial, two analyses were performed: intention-to-treat (ITT) and as-treated (AT) analyses. In the first one, the treatment (OAT) classification at recruitment was retained for the whole follow-up, while in the AT analysis patients who switched treatment were artificially censored (this artificial censoring was also considered in the inverse probability of censoring weights).
Sequential Cox
In order to better evaluate the effect of the time dependent variables, including OAT assumption, on the risk of mortality, thromboembolic events and haemorrhagic events, we evaluated the effect of stopping OAT by the sequential Cox approach [12] . This method mimics several randomized controlled trials, based on individuals stopping OAT in time intervals (of 1 month), and obtains an overall treatment effect estimate. We adjusted for gender and the updated values (at the beginning of each month) of age, percentage of TTR, CHA 2 DS 2 -VAS c and HAS-BLED scores, presence of permanent AF and antiplatelet use.
The effect of suspending OAT was also estimated stratifying patients according to TTR ≥ or <60% [13] . As it was possible that some patients had discontinued therapy because in terminal conditions, a sensitivity analysis was performed in which we censored patients who died within 6 months of warfarin withdrawal.
The proportional hazard assumption was fulfilled in our data.
Score analysis
The Kaplan-Meier estimator was used to describe survival in subgroups defined according to CHA 2 DS 2 -VAS c and HAS-BLED scores at recruitment. We also computed rates of mortality, thromboembolic events and haemorrhagic events by the updated value of the scores during follow-up.
Analyses were carried out by means of the statistical software SAS v.9.4 (SAS Institute Inc., Cary, NC, USA), and R statistical software v.3.1 (http://www.r-project.org).
Results
The study was carried out in a cohort of 290 HD patients, with mean age at recruitment 74 ± 9.7 years. At recruitment, 134 patients (46.2%) were taking OAT (OAT-yes). The median follow-up time was 4 years. During followup, 65/134 (48.5%) patients stopped taking warfarin, while 33/156 (21.1%) patients without OAT at recruitment (OAT-no) started to take it. During the 4-year follow-up there were 170 deaths (95 in OAT-no vs. 75 in OAT-yes at recruitment; 25 and 22 per 100 patient years, respectively; p = 0.4), 28 thromboembolic events (17 in OAT-no vs. 11 in OAT-yes at recruitment; 4.5 and 3.2 per 100 patient years, respectively; p = 0.4) and 95 haemorrhagic events (36 in OAT-no vs. 59 in OAT-yes at recruitment; 9.5 and 17 per 100 patient years, respectively; p = 0.005).
The main causes of death were: cachexia (n = 49, 16.9%), sepsis (n = 34, 11.7%), sudden death (n = 18, 6.3%), and cardiogenic shock and tumor (n = 15, 5.2%). One patient died due to ischemic stroke and three due to hemorrhagic stroke (0.6 and 1.0%, respectively). Table 1 shows the clinical characteristics of the OAT-no and OATyes patients at recruitment, and before and after balancing for treatment propensity.
A Table 2 ). The AT analysis, censoring patients when they switched treatment, showed that patients taking OAT at recruitment had a significantly lower mortality rate than those not taking it, with a non-significant protective effect on thromboembolic events, while a nonsignificant increase in bleedings was observed ( Table 2) .
The results from the sequential Cox regression model showed that among patients taking OAT at recruitment (n = 134), those continuing OAT intake (n = 69) had a significant reduction in the risk of total and cardiovascular mortality compared to patients who stopped the warfarin during follow-up. Warfarin slightly increased the risk of bleeding. In order to evaluate whether the beneficial effect of warfarin on mortality was due to the fact that patients who do not interrupt warfarin have a better INR, we stratified the analysis for TTR lower and higher than 60%: also in patients with a labile INR (TTR <60%) continuous warfarin intake had a beneficial effect. A more marked effect was seen in patients with TTR ≥60% (Table 3 At recruitment, 12 (4.1%) patients had a CHA 2 DS 2 -VAS c score between 0 and 1, 149 (51.4%) between 2 and 4, and 129 (44.5%) between 5 and 9, while for HAS-BLED 3 (1%) patients had a score between 0 and 1, 137 (47.2%) between 2 and 3, and 149 (51.4%) between 4 and 9. Total mortality was significantly related to both CHA 2 DS 2 -VAS c (log-rank test p < 0.001, Fig. 1a ) and HAS-BLED scores (log-rank test p = 0.003, Fig. 1b) . Accordingly, we found higher rates of mortality with higher scores, when the scores were updated during follow-up: 8.4, 18.4, 31.2 per 100 person years for CHA 2 DS 2 -VAS c between 0 and 1, 2-4 and 5-9, respectively, and 0, 17.5, 26.8 per 100 patient years for HAS-BLED between 0 and 1, 2-3 and 4-9, respectively. Thromboembolic events (3.9 per 100 patient years) also increased with higher CHA 2 DS 2 -VAS c score during follow-up (0, 2.1 and 6.1 per 100 patient years for CHA 2 DS 2 -VAS c between 0 and 1, 2-4 and 5-9, respectively) (Fig. 2a) , and similarly bleeding events (13.1 per 100 patient years) increased with higher HAS-BLED score as updated during follow-up (0, 8.5 and 15.6 per 100 patient years HAS-BLED between 0 and 1, 2-3 and 4-9, respectively) (Fig. 2b) .
Discussion
In a population of HD patients with AF, prospectively followed for 4 years, after balancing for treatment propensity, warfarin assumption at recruitment was associated with a non-significant risk reduction in total mortality when an intention-to-treat approach was taken, while the continued warfarin intake was associated with a risk reduction in total mortality of about 50% with an as-treated approach. When subjects who continued to take OAT from recruitment onwards as compared to those who discontinued the treatment were considered, the benefit was also evident for cardiovascular mortality. Taking warfarin was not associated with a significant decrease of thromboembolic events with either approach, even if a trend towards a reduction of thromboembolism and an increase of bleeding in patients receiving OAT was observed in the as-treated analysis. The scores of thromboembolic (CHA 2 DS 2 -VAS c ) and bleeding risk (HAS-BLED) were effective in predicting both events and increased risk of mortality.
Data on the relationship between OAT and risk of death in ESRD patients with AF are not conclusive. Two retrospective studies, evaluating the effect of warfarin on mortality without taking into account the reason for the prescription, showed reduced survival in subjects receiving OAT [14, 15] . More recently, evidence suggesting a protective effect of OAT on the risk of mortality emerged [4, 16] . To understand the relationship between warfarin and risk of death in HD patients with AF is a very complex problem for several reasons. The percentage of people taking OAT is often a minority compared to the number of patients who would have an indication in accordance with the current guidelines. In two recent studies, the prevalence of ESRD subjects with AF receiving warfarin was 8.4% [6] and 6.0% [17] . The underutilization of OAT in the presence of ESRD makes it difficult to compare its effect in the HD population vs. patients with AF, but with preserved renal function. Moreover, a high percentage of HD patients taking OAT suspend it after severe bleeding [6, 7] . For these reasons, the results of intention-to-treat analysis are difficult to interpret. To overcome the problem, Shen et al. in a cohort of HD patients from a registry of newly diagnosed AF patients, performed an as-treated analysis, after applying a propensity score approach to treatment. The authors' conclusion was that patients under OAT had a better survival than those who were not anticoagulated [6] . Applying a similar statistical approach, our study, which has the advantage of being a prospective study where the INR values and the exact date of OAT suspension are known, came to similar conclusions. Moreover, the Cox model evaluating the effect of stopping OAT during follow-up reveals that a drug withdrawal in patients taking OAT at recruitment is accompanied by an increase in mortality from both all and cardiovascular causes. Our preliminary results had suggested the presence of a slight non-significant trend towards a better survival in HD patients with AF taking warfarin, compared to those not anticoagulated [7] . The present study indicates that, for the protective effect of the drug to become evident, it is necessary that only the actual time of warfarin intake is considered. Although patients who benefit most from taking warfarin are those who have a higher TTR, the survival of patients with labile INR is still better than that of those who suspend the drug. In our population, OAT warfarin appears to have a nonsignificant protective effect against the risk of stroke. This finding is in line with recent retrospective studies based on registry data [2, 17] , while only a large Danish study described a clear reduction in the risk of stroke associated with taking warfarin [3] . In the latter study, however, peritoneal dialysis patients and transplant patients were lumped into a group called "renal replacement", and this makes it difficult to compare the results with those of other studies. In most of these studies it is not taken into account that many patients probably discontinued treatment during follow-up, and this weakens their conclusions. Moreover, in all studies, patients taking OAT at recruitment were a minority compared to those who did not take it (from 6 to 25%), except for the Canadian study (46% of OAT patients) [2] . A series of reasons induce nephrologists to be reluctant to prescribe warfarin to their patients, including the fear of bleeding and of causing an increase in vascular calcifications [5, 18] . A recent study [19] shows that ESRD patients with AF have, as previously highlighted [20] , an increased risk of mortality, but not an increased risk of stroke, when accounting for the competing risk of in-hospital death. The authors suggest that the net clinical benefit of stroke prevention for patients on dialysis with AF has to be rethought. In our cohort, the rate of thromboembolic events was relatively low (3.9 per 100 patient years) compared to what was expected, given the elevated CHA 2 DS 2 -VAS c scores. A similar relatively low rate of stroke was previously described in ESRD patients with AF by other authors [21] . Despite the fact that ESRD is associated with an increase of overall stroke (i.e. thromboembolic and thrombotic cerebrovascular events) [22] , in HD patients with AF the incidence of thromboembolic stroke could be lower than expected because of a protective effect of possible platelet disorders present in uremia [23] and the chronic administration, three times a week, of heparin during each HD session. Therefore, we cannot exclude that the protective effect of warfarin against thromboembolic risk can be blunted by the fact that HD patients are already partially anticoagulated. Oral anticoagulation has been shown to protect against myocardial infarction and to be safe and effective in coronary artery disease patients with and without concomitant AF [24, 25] . Moreover a recent study demonstrated in older adults with AF a benefit from OAT in terms of lower mortality, regardless of poor health and functional condition [26] . It is possible that, also in HD patients, OAT might have a survival benefit not only through a reduction of thromboembolic risk, as recently shown by Brancaccio et al. [27] . The rate of bleeding events of our population was extremely high (13.1 per 100 patient years) and significantly exceeded that of thromboembolic events. The haemorrhagic risk tends to increase in patients taking OAT, according to what has already been reported in the literature [2, 7, 15, 21] , and this stresses the importance of a careful assessment of the bleeding risk when deciding whether to start OAT in an ESRD patient. In HD patients with AF and particularly high haemorrhagic risk, alternatives to OAT such as percutaneous occlusion of the left atrial appendage may be considered [28] . In our population, both CHA 2 DS 2 -VAS c and HAS-BLED values were very high and both scores were associated with an increase of total mortality and thromboembolic and haemorrhagic events, respectively. Even if the two scores were originally developed in populations which excluded ESRD subjects, this result confirms that they have some utility in identifying frail patients who need particular attention in warfarin prescription also among the HD population, even if the small percentage of subjects with low scores may reduce the possibility to stratify appropriately patients at lower thromboembolic and bleeding risk. Our study has some limitations and strengths. We cannot be sure that all AF episodes were included in our study, especially paroxysmal forms that often go unrecognized. However we decided to include only cases with a clear electrocardiographic documentation to be sure of the real presence of arrhythmias. Of note, the prevalence of AF in our population was similar to that reported in the literature [29] .
This study basically includes prevalent OAT users, and in order to assess whether it might be subject to the prevalent users bias [30] , we performed a sensitivity analysis including the limited number of incident-users (patients that started OAT intake within 3 months from recruitment, n = 13) and non-users (n = 156). This analysis showed results consistent with the reported analysis [as-treated analysis on mortality: HR 0.21 (0.05-0.82), p = 0.02, OATyes vs. OAT-no patients]. Moreover, a major bias is likely not to be present given that our overall results were similar to those obtained on incident cases of AF by Shen et al. [6] .
Our study, compared to the majority of those available, has the advantage of being prospective and of considering many factors that are useful in guiding clinical practice. However, it has the limitation of not being a randomized trial, even if we carefully considered in our analysis all statistical corrections that allow to limit the bias due to lack of randomization. In our opinion, however, a randomized study has a low feasibility in this context. Our patients often have high haemorrhagic scores and the risk of experiencing bleeding increases with increasing HAS-BLED score. Warfarin is associated with the possibility of suffering bleeding episodes during follow-up. We would be reluctant to randomize a patient with very high HAS-BLED to take OAT and even if we did, there would be a high chance for this patient to drop out due to bleeding. In addition, our data suggest a protective effect of warfarin in terms of mortality, so we would possibly be depriving a HD patient able to take OAT of the opportunity to do so. We acknowledge that the intention-to-treat analysis is hampered by treatment crossover, while as-treated analysis might be subject to selection bias due to adverse events occurring in the follow-up, causing warfarin withdrawal. Those patients who succeeded in continuing to take the therapy could be the ones who were less frail and had a better compliance. However, to assess this assumption, we performed a sensitivity analysis in which we censored patients who died within 6 months of warfarin withdrawal and we obtained similar results. A further limitation is the fact that a 125 g/m 2 cutoff to define LVH may have underestimated the LVH presence in women.
In conclusion, our data suggest that in a HD population presenting both a high thromboembolic and bleeding risk, a protective effect of warfarin on total and cardiovascular mortality is present in patients taking OAT without discontinuations and with INR kept within the therapeutic range. Our study also shows that CHA 2 DS 2 -VAS c and HAS-BLED scores can be useful in HD patients to identify those at highest risk of mortality and thromboembolic and bleeding events.
